http://hl7.org/fhir/uv/ebm/Evidence/557352
type: Evidence
node role: treeRoot
id:
  v: 557352
meta:
  version id:
    v: 1
  last updated:
    v: 2026-04-08T13:56:39.431Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence
    l: comparative-evidence
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: Evidence 557352 version: 1; Last updated: 2026-04-08 13:56:39+0000 Profile: ComparativeEvidence ArtifactPublicationStatus: Active url: https://fevir.net/resources/Evidence/557352 identifier: FEvIR Object Identifier/557352, outcomeId/313959, picoId/85798, sectionId/73215 name: Nonfatal_stroke_from_MAGICapp_313959 title: MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes citeAs: MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557352. Revised 2026-04-08. Available at: https://fevir.net/resources/Evidence/557352. Computable resource at: https://fevir.net/resources/Evidence/557352#json. status: Active author: Computable Publishing®: MAGIC-to-FEvIR Converter: publisher: Computable Publishing LLC contact: support@computablepublishing.com UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ComparativeEvidence copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ RelatesTos - Type Target[x] * Part Of MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report) description: This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide. assertion: SGLT2 inhibitors probably increase the risk of nonfatal stroke compared with GLP-1 receptor agonists. variableDefinition description: Adults with type 2 diabetes variableRole: Population observed: Adults with type 2 diabetes and CVD and CKD variableDefinition description: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA variableRole: Exposure comparatorCategory: GLP-1 RA observed: GroupAssignment: SG…
extension:
  url:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
    l: artifact-publication-status
  value: CodeableConcept
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
        l: cited-artifact-status-type
      code:
        v: active
      display:
        v: Active
url:
  v: https://fevir.net/resources/Evidence/557352
  l: https://fevir.net/resources/Evidence/557352
identifier:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v2-0203
        l: v2-0203
      code:
        v: ACSN
      display:
        v: Accession ID
    text:
      v: FEvIR Object Identifier
  system:
    v: https://fevir.net/FOI
    l: FOI
  value:
    v: 557352
  assigner:
    display:
      v: Computable Publishing LLC
identifier:
  type:
    text:
      v: outcomeId
  system:
    v: https://app.magicapp.org/#/guidelines
    l: guidelines
  value:
    v: 313959
identifier:
  type:
    text:
      v: picoId
  system:
    v: https://app.magicapp.org/#/guidelines
    l: guidelines
  value:
    v: 85798
identifier:
  type:
    text:
      v: sectionId
  system:
    v: https://app.magicapp.org/#/guidelines
    l: guidelines
  value:
    v: 73215
name:
  v: Nonfatal_stroke_from_MAGICapp_313959
title:
  v: MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
cite as:
  v: MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557352. Revised 2026-04-08. Available at: https://fevir.net/resources/Evidence/557352. Computable resource at: https://fevir.net/resources/Evidence/557352#json.
status:
  v: active
author:
  name:
    v: Computable Publishing®: MAGIC-to-FEvIR Converter
publisher:
  v: Computable Publishing LLC
contact:
  telecom:
    system:
      v: email
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ComparativeEvidence
      display:
        v: ComparativeEvidence
copyright:
  v: https://creativecommons.org/licenses/by-nc-sa/4.0/
relates to:
  type:
    v: part-of
  target: Reference
    type:
      v: Composition
      l: Composition
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-conversion-report
    display:
      v: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes
description:
  v: This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
assertion:
  v: SGLT2 inhibitors probably increase the risk of nonfatal stroke compared with GLP-1 receptor agonists.
variable definition:
  description:
    v: Adults with type 2 diabetes
  variable role:
    v: population
  observed:
    l: http://hl7.org/fhir/uv/ebm/Group/236947
    reference:
      v: Group/236947
    type:
      v: Group
      l: Group
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-population-group-85394-85798
    display:
      v: Adults with type 2 diabetes and CVD and CKD
variable definition:
  description:
    v: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
  variable role:
    v: exposure
  comparator category:
    v: GLP-1 RA
  observed:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236950
    reference:
      v: EvidenceVariable/236950
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-group-assignment-85394-85798
    display:
      v: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
variable definition:
  description:
    v: Nonfatal stroke
  variable role:
    v: outcome
  observed:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236962
    reference:
      v: EvidenceVariable/236962
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-313959
    display:
      v: Nonfatal stroke

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

text:
  v: SYSTEMATIC_REVIEW

text:
  v: NOTSET

description:
  v: Risk Difference 2.7% (CI95 0.4% to 5.3%)
statistic type:
  coding:
    system:
      v: https://fevir.net/sevco
      l: sevco
    code:
      v: STATO:0000424
    display:
      v: risk difference
quantity:
  value:
    v: 0.027
sample size:
  number of studies:
    v: 2
  number of participants:
    v: 1282
attribute estimate:
  type:
    text:
      v: CI95
  range:
    low:
      value:
        v: 0.004
    high:
      value:
        v: 0.053

description:
  v: OR 1.2 (CI95 1.03 to 1.41)
statistic type:
  coding:
    system:
      v: https://fevir.net/sevco
      l: sevco
    code:
      v: STATO:0000182
    display:
      v: odds ratio
quantity:
  value:
    v: 1.2
sample size:
  number of studies:
    v: 2
  number of participants:
    v: 1282
attribute estimate:
  type:
    text:
      v: CI95
  range:
    low:
      value:
        v: 1.03
    high:
      value:
        v: 1.41

description:
  v: Due to serious imprecision
type:
  coding:
    system:
      v: http://hl7.org/fhir/certainty-type
      l: certainty-type
    code:
      v: Overall
    display:
      v: Overall certainty
rating:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/27834
      l: https://fevir.net/resources/CodeSystem/27834
    code:
      v: RJCS-2004
    display:
      v: Moderate certainty
subcomponent:
  type:
    text:
      v: Risk of Bias
  rating:
    text:
      v: NOTSET
subcomponent:
  type:
    text:
      v: Inconsistency
  rating:
    text:
      v: NOTSET
subcomponent:
  type:
    text:
      v: Indirectness
  rating:
    text:
      v: NOTSET
subcomponent:
  type:
    text:
      v: Imprecision
  rating:
    text:
      v: NOTSET
subcomponent:
  type:
    text:
      v: Publication Bias
  rating:
    text:
      v: NOTSET